Dupilumab: Broad Efficacy in Type 2 Inflammation with Dose-Dependent Clearance

Analysis of dosing regimens, pharmacokinetics, and safety profiles across 5 major indications

Design Drug Monograph Analysis Population Adults & Pediatrics (≥6 months) N Not specified (Pooled Trials) Duration Maintenance Therapy Comparator Standard of Care / Placebo (implied) Year 2024

Key Performance Indicators

PRIMARY

Bioavailability

64%

Range: 61-64%

Subcutaneous absorption

Max Clearance Time

13

Weeks (post-discontinuation)

For 300mg weekly dose

Injection Site Reactions

38%

Upper limit incidence

Most common AE

Vol. of Distribution

4.8

± 1.3 L

Limited tissue distribution

01

Eosinophilic Esophagitis requires the highest maintenance dosing intensity

While most indications stabilize on a bi-weekly schedule, EoE necessitates weekly administration to maintain efficacy.

02

Local reactions and URIs dominate the adverse event profile

Injection site reactions are the most prevalent adverse event, occurring in up to 38% of patients, followed by respiratory infections.

03

Systemic clearance time correlates with total weekly dosage

Higher aggregate weekly doses result in prolonged washout periods, extending up to 13 weeks for the 300mg weekly regimen.

04

Pediatric Atopic Dermatitis dosing escalates strictly by weight tier

Dosing frequency increases from monthly to bi-weekly as patient weight crosses the 30kg threshold.

05

Bioavailability indicates efficient subcutaneous absorption

With a bioavailability of up to 64%, Dupilumab demonstrates robust systemic uptake from subcutaneous injection.

06

Wholesale pricing favors the 300mg formulation on a per-mL basis

While the per-dose cost is similar (~$2,280), the 300mg/2mL formulation is significantly cheaper per milliliter than the 200mg/1.14mL option.

Editorial Conclusion

“Dupilumab offers a versatile therapeutic option for Type 2 inflammatory diseases, though its dosing complexity and clearance profile require careful management.”

Safety profile is largely manageable, dominated by local injection reactions (38%) and URIs (18%).

Clearance is slow and dose-dependent, taking up to 13 weeks for high-frequency regimens.

Ocular side effects like conjunctivitis (10%) are a specific concern distinguishing it from other biologics.

Clinical Implication

Clinicians must tailor dosing strictly to indication and weight (in pediatrics) while monitoring for ocular and local injection site adverse events.

Reference Data & Sources

Complete Data Table

viz_id	chart_type	label	group	value	value_text	low	high	unit	category	x	y	target	rank
viz1	horizontal_bar	Eosinophilic Esophagitis	Indication	1	Weekly				Dosing
viz1	horizontal_bar	Atopic Dermatitis	Indication	0.5	Every 2 Weeks				Dosing
viz1	horizontal_bar	Asthma (Severe)	Indication	0.5	Every 2 Weeks				Dosing
viz1	horizontal_bar	CRSwNP	Indication	0.5	Every 2 Weeks				Dosing
viz1	horizontal_bar	Prurigo Nodularis	Indication	0.5	Every 2 Weeks				Dosing
viz2	lollipop	Injection-site reaction	Local	38	38%								1
viz2	lollipop	Upper respiratory infection	Infection	18	18%								2
viz2	lollipop	Antibody development	Immunologic	16	16%								3
viz2	lollipop	Conjunctivitis	Ophthalmic	10	10%								4
viz2	lollipop	Nasopharyngitis	Respiratory	5	5%								5
viz2	lollipop	Herpes virus infection	Infection	4	4%								6
viz2	lollipop	Dizziness	Nervous System	3	3%								7
viz2	lollipop	Eosinophilia	Hematologic	3	<3%								8
viz3	scatter	300mg Weekly	High Dose		13 weeks					300	13
viz3	scatter	300mg Q2W	Medium Dose		10-11 weeks					150	10.5
viz3	scatter	200mg Q2W	Low Dose		9 weeks					100	9
viz4	heatmap	15 to <30 kg	Dose (mg)	300	300mg
viz4	heatmap	15 to <30 kg	Frequency (Weeks)	4	Every 4 Weeks
viz4	heatmap	30 to <60 kg	Dose (mg)	200	200mg
viz4	heatmap	30 to <60 kg	Frequency (Weeks)	2	Every 2 Weeks
viz4	heatmap	≥60 kg	Dose (mg)	300	300mg
viz4	heatmap	≥60 kg	Frequency (Weeks)	2	Every 2 Weeks
viz5	gauge	Bioavailability		64		61	64	%				100
viz6	paired_bar	200mg/1.14mL Pen	Price per mL ($)	2001.68					Cost
viz6	paired_bar	300mg/2mL Pen	Price per mL ($)	1140.96					Cost

Abbreviations

Abbrev	Meaning
EoE	Eosinophilic Esophagitis
CRSwNP	Chronic Rhinosinusitis with Nasal Polyposis
Q2W	Every 2 Weeks
Q4W	Every 4 Weeks

Source

UpToDate, Inc. 2024

Limitations

Pricing data reflects AWP and may not represent actual acquisition cost.
Adverse event rates are pooled from labeling and may vary by specific indication.